Targeting the TRIM21-PD-1 Axis Potentiates Immune Checkpoint Blockade and CAR T Cell Therapy

Researchers reported that TRIM21 impaired CD8+ T cell activation and anti-tumor immunity. Mechanistically, TRIM21 catalyzed the K63-linked ubiquitination on PD-1 at K233, leading to stabilization of PD-1 through antagonizing its K48-linked ubiquitination and degradation.